Blueprint Medicines Corporation - BPMC STOCK NEWS

Blueprint Medicines Corporation (NASDAQ:BPMC) reported second quarter 2021 financial results, revealing revenues of $27.3 million, a significant increase from $8.3 million in Q2 2020. This growth was fueled by $8.5 million in product sales from AYVAKIT and $2.9 million from GAVRETO. The company recorded a net loss of $108.4 million or $1.86 per share. AYVAKIT was recently approved for advanced systemic mastocytosis, while ongoing trials for BLU-945 and BLU-263 mark significant steps in their clinical pipeline. Cash reserves stood at $1.38 billion as of June 30, 2021.

Blueprint Medicines Corporation (BPMC) and MD Anderson Cancer Center announced a three-year strategic research collaboration to advance BLU-222, a precision therapy targeting cyclin-dependent kinase 2 (CDK2). The partnership aims to explore cancer types responsive to this selective CDK2 inhibitor, develop mono- and combination therapies, and identify biomarkers for treatment response. Blueprint Medicines plans to initiate a Phase 1 clinical trial of BLU-222 in patients with CCNE-aberrant cancers by mid-2022. MD Anderson will receive payments based on future development stages of BLU-222.

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call on July 29, 2021 at 8:30 a.m. ET to disclose its second quarter 2021 financial results and provide a corporate update. Interested parties can join the call by dialing 844-200-6205 domestically or +44-208-0682-558 internationally, using conference ID 619159. A webcast will be accessible via the Investors & Media section on their website and will remain available for 30 days post-call. Blueprint Medicines focuses on developing targeted therapies for cancer and hematologic disorders.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of stock options and restricted stock units (RSUs) to 12 new employees under its 2020 Inducement Plan. Effective July 1, 2021, the Compensation Committee approved 25,762 stock options with an exercise price of $87.66 per share and 12,880 RSUs. The options vest 25% after one year, then monthly over four years. The RSUs vest 25% annually for four years, both subject to continued employment. This initiative aims to attract talent critical for the company's focus on precision therapies for genomically defined cancers and rare diseases.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced that the FDA approved AYVAKIT™ (avapritinib) for adult patients with advanced systemic mastocytosis (Advanced SM), marking a significant milestone in targeted therapy for this rare disease. This approval, based on clinical trials showing a 57% overall response rate, allows patients access to a treatment that specifically inhibits the D816V mutant KIT, which drives the disease. AYVAKIT is available in various doses and aims to improve outcomes for patients suffering from this debilitating illness.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of non-qualified stock options and restricted stock units to seven new employees, effective June 1, 2021. The total includes 49,102 stock options and 26,793 RSUs. Chief Scientific Officer Percy Carter received options for 39,200 shares and 21,843 RSUs. The options have an exercise price of $89.16, equal to the stock's closing price on the grant date. The awards are part of the 2020 Inducement Plan, aimed at attracting new talent under NASDAQ Listing Rule 5635(c)(4).

Blueprint Medicines Corporation (NASDAQ: BPMC) has announced its participation in several upcoming investor conferences. These include:

• Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET.
• Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:50 a.m. ET.
• JMP Securities Life Sciences Conference on June 16, 2021, at 1:00 p.m. ET.

Live webcasts will be available on the company's website, with replays accessible for 30 days post-presentation.

Blueprint Medicines (NASDAQ: BPMC) announced promising results from the Phase 1/2 ARROW trial of GAVRETO® (pralsetinib) for metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Data show an overall response rate (ORR) of 79% in treatment-naïve patients and 62% in those previously treated with chemotherapy. The safety profile remained consistent, with no new signals reported. These findings will be presented at the ASCO Annual Meeting from June 4-8, 2021, highlighting GAVRETO’s potential to redefine first-line treatments for RET-altered cancers.

Blueprint Medicines Corporation (NASDAQ: BPMC) appointed Percy Carter, MBA, Ph.D., as its Chief Scientific Officer, effective May 19, 2021. Dr. Carter will oversee research and preclinical development, aiming to enhance the company's precision therapy pipeline focused on oncology and hematology. He brings over 20 years of experience from previous roles at FibroGen, Janssen Pharmaceuticals, and Bristol-Myers Squibb. The leadership change is positioned to accelerate Blueprint's ability to deliver innovative therapies for patients.